8-KOther Events

ABBOTT LABORATORIES 8-K Report, Corporate Update (Oct 18, 2012)

Filed October 18, 2012For Securities:ABT

Summary

Abbott Laboratories (ABT) reported on October 18, 2012, that Reata Pharmaceuticals, the developer of bardoxolone methyl, has discontinued its Phase 3 clinical study (BEACON) for advanced chronic kidney disease (CKD) and type 2 diabetes. This decision stems from a recommendation by the study's Independent Data Monitoring Committee (IDMC) due to safety concerns, specifically citing "excess serious adverse events and mortality" in the bardoxolone methyl treatment arm. While this discontinuation represents a setback for the potential development of bardoxolone methyl in this specific indication, both Reata and Abbott plan to thoroughly analyze the study data to assess if there's a viable path forward for the drug in CKD or other potential uses. Abbott holds the rights to bardoxolone methyl outside the U.S., excluding certain Asian markets, making this news relevant to its international pipeline and future revenue potential.

Key Highlights

  • 1Reata Pharmaceuticals discontinued the Phase 3 BEACON clinical study for bardoxolone methyl in advanced CKD and type 2 diabetes.
  • 2The discontinuation was due to safety concerns identified by the Independent Data Monitoring Committee (IDMC).
  • 3Serious adverse events and mortality were higher in the bardoxolone methyl treatment group.
  • 4Regulatory agencies have been notified of the study's discontinuation.
  • 5Abbott Laboratories and Reata Pharmaceuticals will analyze study data to determine future development paths for bardoxolone methyl.
  • 6Abbott has ex-U.S. rights (excluding certain Asian markets) to bardoxolone methyl.

Frequently Asked Questions

The BEACON study was discontinued due to safety concerns identified by the Independent Data Monitoring Committee (IDMC), which observed excess serious adverse events and mortality in patients treated with bardoxolone methyl.

Abbott Laboratories holds the rights to develop and market bardoxolone methyl outside of the United States, with the exception of certain Asian markets.

Not necessarily. Abbott and Reata Pharmaceuticals intend to examine the study data closely to see if there's an appropriate path forward for bardoxolone methyl, either in chronic kidney disease or for other potential indications.

The discontinuation of a Phase 3 trial for a drug with ex-U.S. rights could impact Abbott's future revenue projections and R&D investment strategy. However, the full financial impact will depend on the outcome of the data analysis and any potential alternative development paths for bardoxolone methyl.